{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:19:58Z","timestamp":1773922798437,"version":"3.50.1"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Outcome of diffuse large B-cell lymphoma (DLBCL) with a germinal center B-cell (GCB) expression profile is superior to that of non-GCB DLBCL. This conclusion is mainly derived from patients with mixed international prognostic index (IPI) risk profiles treated with CHOP-like therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). We wondered whether the prognostic impact of the expression profile would hold out in a homogeneous cohort of poor-risk DLBCL patients treated with high-dose sequential therapy (HDT) and autologous stem-cell transplantation (ASCT) as first-line therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> DLBCL from 66 newly diagnosed poor-risk patients, treated in two sequential prospective Dutch Hemato-Oncology Association (HOVON) trials, were studied retrospectively for expression of CD10, bcl6, MUM1\/IRF4, bcl2, Ki67, and CD21<jats:sup>+<\/jats:sup> follicular dendritic cells (FDC) by immunohistochemistry, and for the breakpoints of BCL2, BCL6, and MYC by fluorescent in situ hybridization (FISH). Lymphomas with any follicular component were excluded. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A GCB immunophenotype profile was found in 58% and non-GCB immunophenotype profile in 42% of the tumors. Clinical characteristics of both groups were similar. Complete response (CR) rate was higher in patients with CD10<jats:sup>+<\/jats:sup> tumors (58% v 30%; P = .03). A GCB immunophenotype profile, its constituting markers CD10 more than 30% and MUM1 less than 70%, and bcl2 less than 10% were each associated with a better overall survival (OS). FDC networks, equally present in GCB and non-GCB tumors, had superior CR (73% v 31%; P = .01), but disease-free survival rates were lower and there was no difference in OS rates. None of the breakpoints had a prognostic impact on outcome. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Also in patients with poor-risk DLBCL treated with HDT and ASCT, the GCB immunophenotype and bcl2 expression retained a major impact on survival. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.05.5897","type":"journal-article","created":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T00:39:21Z","timestamp":1156984761000},"page":"4135-4142","source":"Crossref","is-referenced-by-count":134,"title":["Prognostic Impact of Germinal Center\u2013Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma"],"prefix":"10.1200","volume":"24","author":[{"given":"Gustaaf W.","family":"van Imhoff","sequence":"first","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evert-Jan G.","family":"Boerma","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo F.","family":"Verdonck","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Kluin","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology and Pathology, University Medical Center Groningen, University of Groningen, Groningen; Department of Trials and Statistics\u2013HOVON Data Center, Erasmus MC\u2013Daniel den Hoed Cancer Center, Rotterdam; and the Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Jaffe ES, Harris NL, Stein H, et al: World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues, in: IARC WHO Classification of Tumours.  Lyon, France, IARC Press; 2001"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3152"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2003.01758.x"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1732008100"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-68"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00429.x"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1286"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00005"},{"key":"R13","unstructured":"Zinzani PL, Dirnhofer S, Sabattini E, et al: Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 90:341,2005-347,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.15.503"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800396"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.039"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Haralambieva E, Boerma EJ, van Imhoff GW, et al: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 29:1086,2005-1094,","DOI":"10.1097\/01.pas.0000168176.71405.e5"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.1.234.413k22_234_240"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.1168"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2285"},{"key":"R21","unstructured":"Barrans SL, Evans PA, O'Connor SJ, et al: The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9:2133,2003-2139,"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200006000-00010"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01196.x"},{"key":"R24","unstructured":"Linderoth J, Jerkeman M, Cavallin-Stahl E, et al: Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: A Nordic Lymphoma Group Study. Clin Cancer Res 9:722,2003-728,"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-1129-7"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02099.x"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1038\/ng0697-161"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3387"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.945"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2084"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63150-1"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1603"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1136"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.244"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.265.265"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1046.1046"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3442"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63313-5"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.05.5897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:25:36Z","timestamp":1653513936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.05.5897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":40,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2006,9,1]]}},"alternative-id":["10.1200\/JCO.2006.05.5897"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.05.5897","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}